387 related articles for article (PubMed ID: 27447750)
1. Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma.
Carbone M; Shimizu D; Napolitano A; Tanji M; Pass HI; Yang H; Pastorino S
Oncotarget; 2016 Sep; 7(37):59314-59321. PubMed ID: 27447750
[TBL] [Abstract][Full Text] [Related]
2. [Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application].
Guo ZY; Sun WY; Michele Y; Zhang JL; Hu D; Su HN; Yang WM; Mao W
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):699-703. PubMed ID: 29050072
[No Abstract] [Full Text] [Related]
3. The role of BRCA1-associated protein 1 in the diagnosis of malignant mesothelioma in effusion and fine-needle aspiration cytology.
Hatem L; McIntire PJ; He B; Gogineni S; Ho M; Mathew S; Margolskee EM; Siddiqui MT; Rao RA
Diagn Cytopathol; 2019 Mar; 47(3):160-165. PubMed ID: 30520251
[TBL] [Abstract][Full Text] [Related]
4. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
[TBL] [Abstract][Full Text] [Related]
5. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.
Kinoshita Y; Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Hiroshima K; Oda Y; Nabeshima K
Cancer Cytopathol; 2018 Jan; 126(1):54-63. PubMed ID: 29053210
[TBL] [Abstract][Full Text] [Related]
6. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
[TBL] [Abstract][Full Text] [Related]
7. BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
Pathol Int; 2016 Oct; 66(10):563-570. PubMed ID: 27614970
[TBL] [Abstract][Full Text] [Related]
8. Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions.
Cozzi I; Oprescu FA; Rullo E; Ascoli V
Diagn Cytopathol; 2018 Jan; 46(1):9-14. PubMed ID: 28994508
[TBL] [Abstract][Full Text] [Related]
9. 5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies.
Alsugair Z; Kepenekian V; Fenouil T; Glehen O; Villeneuve L; Isaac S; Hommell-Fontaine J; Benzerdjeb N
Virchows Arch; 2022 Jul; 481(1):23-29. PubMed ID: 35575935
[TBL] [Abstract][Full Text] [Related]
10. Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.
Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Nabeshima K
Pathol Int; 2020 Sep; 70(9):671-679. PubMed ID: 32542810
[TBL] [Abstract][Full Text] [Related]
11. Comparison of immunohistochemical mesothelial biomarkers in paired biopsies and effusion cytology cell blocks from pleural mesothelioma.
Mansour MSI; Huseinzade A; Seidal T; Hejny K; Maty A; Taheri-Eilagh F; Mager U; Dejmek A; Dobra K; Brunnström H
Cytopathology; 2023 Sep; 34(5):456-465. PubMed ID: 37337638
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic application of BAP1 immunohistochemistry to differentiate pleural mesothelioma from metastatic pleural tumours.
Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Nabeshima K
Histopathology; 2017 Dec; 71(6):1011-1014. PubMed ID: 28746778
[No Abstract] [Full Text] [Related]
13. High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.
Nasu M; Emi M; Pastorino S; Tanji M; Powers A; Luk H; Baumann F; Zhang YA; Gazdar A; Kanodia S; Tiirikainen M; Flores E; Gaudino G; Becich MJ; Pass HI; Yang H; Carbone M
J Thorac Oncol; 2015 Apr; 10(4):565-76. PubMed ID: 25658628
[TBL] [Abstract][Full Text] [Related]
14. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K
Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study.
Hakim SA; Abou Gabal HH
Pathol Oncol Res; 2021; 27():600073. PubMed ID: 34257556
[No Abstract] [Full Text] [Related]
16. Diagnostic utility of BAP1 for malignant pleural mesothelioma in pleural fluid specimens with atypical morphology.
Louw A; Lee YCG; Acott N; Creaney J; van Vliet C; Chai SM
Cytopathology; 2022 Jan; 33(1):84-92. PubMed ID: 34033161
[TBL] [Abstract][Full Text] [Related]
17. About the diagnostic value of BAP-1 antibody in malignant pleural mesothelioma: a meta-analysis.
Mlika M; Zorgati M; BenKhelil M; Mezni FE
J Immunoassay Immunochem; 2019; 40(3):269-282. PubMed ID: 30810450
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical evaluation of nuclear 5-hydroxymethylcytosine (5-hmC) accurately distinguishes malignant pleural mesothelioma from benign mesothelial proliferations.
Chapel DB; Husain AN; Krausz T
Mod Pathol; 2019 Mar; 32(3):376-386. PubMed ID: 30315275
[TBL] [Abstract][Full Text] [Related]
19. [BRCA1 associated protein 1 (BAP1) expression in pleural diffuse malignant mesothelioma: A comparative cytological and histological analyses on 50 patients].
Jaouen A; Thivolet-Bejui F; Chalabreysse L; Piaton E; Traverse-Glehen A; Isaac S; Decaussin-Petrucci M; Depaepe L; Fontaine J; Remy I; Maury JM; Brevet M
Ann Pathol; 2016 Apr; 36(2):111-9. PubMed ID: 26995100
[TBL] [Abstract][Full Text] [Related]
20. BAP1 and Claudin-4, But Not MTAP, Reliably Distinguish Borderline and Low-grade Serous Ovarian Tumors From Peritoneal Mesothelioma.
Devins KM; Zukerberg L; Watkins JC; Hung YP; Oliva E
Int J Gynecol Pathol; 2023 Mar; 42(2):159-166. PubMed ID: 35512220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
